Italia markets close in 8 hours 11 minutes

Abcam plc (A8C3.F)

Frankfurt - Frankfurt Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
13,000,00 (0,00%)
Al 09:16AM CEST. Mercato aperto.
Schermo intero
Chiusura precedente13,00
Aperto13,00
Denaro0,00 x N/D
Lettera0,00 x N/D
Min-Max giorno12,80 - 12,80
Intervallo di 52 settimane11,70 - 20,80
Volume60
Media Volume0
Capitalizzazione3,049B
Beta (5 anni mensile)0,71
Rapporto PE (ttm)590,91
EPS (ttm)0,02
Prossima data utiliN/D
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1A1.702,05
  • GlobeNewswire

    Abcam Plc Results for the 12- and 18-month periods ended 31 December 2021

    Growing demand for Abcam’s portfolio of in-house products drives calendar 2021 revenues up by 22% at constant exchange rates Acquisition of BioVision completed 26 October 2021 CAMBRIDGE, United Kingdom, March 14, 2022 (GLOBE NEWSWIRE) -- Abcam plc (Nasdaq: ABCM; AIM: ABC) (‘Abcam’, the ‘Group’ or the ‘Company’), a global leader in the supply of life science research tools, today announces its final results for the 18-month period ended 31 December 2021 (the ‘period’). The Group’s accounting refe

  • GlobeNewswire

    Nautilus and Abcam Announce Strategic Partnership to Accelerate Exploration of the Proteome

    As an element of Nautilus’ overall reagent development and sourcing strategy, the partnership aims to accelerate research and development, and provide customers with access to Abcam’s antibody development technology and expertiseSEATTLE and CAMBRIDGE, United Kingdom, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, and Abcam (AIM:ABC; NASDAQ:ABCM), a global

  • GlobeNewswire

    29% Constant Currency Revenue Growth in H2 as Lab Activity Gradually Recovers and Demand for Abcam In-house Products Increases

    CAMBRIDGE, United Kingdom, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Abcam plc (Nasdaq: ABCM; AIM: ABC) (‘Abcam’, the ‘Group’ or the ‘Company’), a global leader in the supply of life science research tools, today announces its interim results for the six- and 12-month periods ended 30 June 2021 (the ‘period’). The Group’s accounting reference date has changed from 30 June to 31 December1, therefore these interim financial statements report on both a six- and 12-month period. SUMMARY PERFORMANCE 12 mont